Gastroenterology strain | Irritable bowel syndrome
Characteristics
DAILY DOSAGE IN CLINICAL STUDY
1-5 billion CFU
FUNCTIONALITY
IBS – Irritable bowel syndrome
Scientific support
Human clinical trial
Brenner, DM, and WD Chey. “Bifidobacterium Infantis 35624: A Novel Probiotic for the Treatment of IBS.” Reviews in Gastroenterological Disorders 9.1 (2009): 7-15.
Quigley, EM, PJ Whorwell, L. Altringer, J. Morel, L. O’Mahony, and F. Shanahan. “Probiotic Use Results in Normalization of Bowel Movement Frequency in IBS. Results from a Clinical Trial with the Novel Probiotic Bifidobacterium Infantis 35624.” American Journal of Gastroenterology 100.S9 (2005): S326.
Whorwell, P., L. Altringer, J. Morel, Y. Bond, D. Charbonneau, L. O’Mahony, B. Kiely, F. Shanahan, and EM Quigley. “Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Women with Irritable Bowel Syndrome.” American Journal of Gastroenterology 101 (2006): 1581-590.
O’Mahony, L., J. Mccarthy, P. Kelly, G. Hurley, F. Luo, K. Chen, G. C. O’Sullivan, B. Kiely, J. K. Collins, F. Shanahan, and E. M. Quigley. “Lactobacillus and Bifidobacterium in Irritable Bowel Syndrome: Symptom Responses and Relationship to Cytokine Profiles.” Gastroenterology 128.3 (2005): 541-51.
